VIVS · XBRL financial data

VivoSim Labs financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (VIVS's year ends in late March)

In thousands of dollars	Q2 FY23Sep 30, 2023	Q3 FY23Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY25Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY25Jun 30, 2025	Q2 FY25Sep 30, 2025	Q3 FY25Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY27Jun 30, 2026
Revenue from contracts with customers	0	5	29*	39	30	24	51*	37	28	26	40*	18
Cost of goods and services sold	0	0	—	2	1	2	0*	0	0	0	0*	—
Research and development	1,335	1,434	1,063*	1,402	984	1,780	859*	1,001	923	1,140	1,125*	1,132
Selling, general and administrative	2,780	2,251	2,062*	2,021	1,653	1,710	2,346*	1,951	1,740	1,636	2,102*	1,645
Operating income (loss)	(4,115)	(3,680)	(3,096)*	(3,386)	(2,608)	(3,468)	(3,154)*	(2,915)	(2,635)	(2,750)	(3,187)*	(2,759)
Interest income	121	76	51*	44	59	26	11*	76	92	63	36*	28
Interest expense	—	0	—	0	0	5	5*	4	0	4	4*	4
Income tax expense (benefit)	0	0	0*	2	0	0	0*	0	2	0	0*	3
Net income (loss)	(3,994)	(3,604)	(3,045)*	(3,344)	(2,549)	(3,447)	6,852*	(2,843)	(2,545)	(2,691)	(5,764)*	(1,338)
Earnings per share, basic‡ USD per share	(5.52)	(4.80)	(3.60)*	(2.76)	(1.68)	(2.28)	—	(1.14)	(0.98)	(1.03)	(2.19)*	(0.25)
Earnings per share, diluted‡ USD per share	(5.52)	(4.80)	(3.60)*	(2.76)	(1.68)	(2.28)	—	(1.14)	(0.98)	(1.03)	(2.19)*	(0.25)
Weighted average shares, basic‡ thousands of shares	726	759	836*	1,221	1,499	1,504	1,631*	2,504	2,605	2,608	2,637*	5,239
Weighted average shares, diluted‡ thousands of shares	726	759	836*	1,221	1,499	1,504	1,631*	2,504	2,605	2,608	2,637*	5,239

‡ Per-share figures and share counts are adjusted for the 1-for-12.004801920768308 stock split (March 2025); filings made before it reported them unadjusted.

Balance sheet

CSV

Fiscal quarters (VIVS's year ends in late March)

In thousands of dollars	Q2 FY23Sep 30, 2023	Q3 FY23Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY25Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY25Jun 30, 2025	Q2 FY25Sep 30, 2025	Q3 FY25Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY27Jun 30, 2026
Cash and cash equivalents	7,617	5,295	2,901	6,187	3,174	1,161	11,312	9,055	6,677	4,288	5,024	1,670
Accounts receivable	55	33	33	48	29	26	30	32	32	33	32	29
Inventory	—	—	297	408	640	0	0	—	—	—	—	—
Prepaid and other current assets	624	913	705	640	940	913	789	592	882	709	557	511
Total current assets	8,296	6,241	3,936	7,283	4,783	2,100	12,131	9,679	7,591	6,041	6,627	3,226
Property and equipment, net	808	739	669	601	545	479	419	359	300	248	206	189
Right-of-use asset	1,505	1,403	1,299	1,194	1,086	978	867	755	641	525	407	287
Total assets	11,161	8,881	6,349	9,470	6,754	3,844	14,650	11,978	9,686	6,960	7,386	3,847
Accounts payable	435	471	627	1,119	419	930	1,644	673	580	671	1,021	621
Accrued liabilities	666	727	727	404	879	1,015	1,226	727	771	818	981	738
Total current liabilities	1,600	1,700	1,860	2,033	2,414	2,937	3,737	2,142	2,449	2,475	2,785	1,893
Lease liability, non-current	1,105	999	888	775	660	543	421	298	172	44	0	0
Total liabilities	2,705	2,699	2,748	2,808	3,074	3,480	4,158	2,440	2,621	2,519	8,485	6,193
Accumulated deficit	(333,020)	(336,624)	(339,669)	(343,013)	(345,562)	(349,009)	(342,157)	(345,000)	(347,545)	(350,236)	(356,000)	(357,338)
Total stockholders' equity	8,456	6,182	3,601	6,662	3,680	364	10,492	9,538	7,065	4,441	(1,099)	(2,346)
Total liabilities and equity	11,161	8,881	6,349	9,470	6,754	3,844	14,650	11,978	9,686	6,960	7,386	3,847
Common shares outstanding (cover page)‡ thousands of shares	736	836	1,197	1,280	1,280	1,454	2,600	2,600	2,608	2,608	3,494	14,851

‡ Per-share figures and share counts are adjusted for the 1-for-12.004801920768308 stock split (March 2025); filings made before it reported them unadjusted.

Cash flows

CSV

Fiscal quarters (VIVS's year ends in late March)

In thousands of dollars	Q2 FY23Sep 30, 2023	Q3 FY23Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY25Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY25Jun 30, 2025	Q2 FY25Sep 30, 2025	Q3 FY25Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY27Jun 30, 2026
Net income (loss)	(3,994)	(3,604)	(3,045)*	(3,344)	(2,549)	(3,447)	6,852*	(2,843)	(2,545)	(2,691)	(5,764)*	(1,338)
Depreciation and amortization	71*	71*	71*	70	68*	67*	61*	61	59*	52*	43*	40
Net cash from operating activities	(3,149)*	(3,522)*	(2,671)*	(2,983)	(2,642)*	(1,801)*	(2,035)*	(3,940)	(2,378)*	(2,271)*	(2,238)*	(3,213)
Purchases of property and equipment	27*	0*	0*	0	13*	0*	0*	0	0*	0*	0*	23
Net cash from investing activities	12*	27*	13*	20	0*	4*	9,001*	0	0*	0*	94*	(23)
Proceeds from issuing common stock	0*	1,173*	264*	6,249	(371)*	(216)*	3,185*	1,811	0*	0*	2,997*	0
Net cash from financing activities	0*	1,173*	264*	6,249	(371)*	(216)*	3,185*	1,683	0*	(118)*	2,880*	(118)
Net change in cash	(3,137)*	(2,322)*	(2,394)*	3,286	(3,013)*	(2,013)*	10,151*	(2,257)	(2,378)*	(2,389)*	736*	(3,354)

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
VivoSim Labs	1,670	18	(3,213)	14.9M	0.5 quarters	Q1 FY27 10-QJun 30, 2026
Genprex	15,154	not reported	(5,139)*	819,709	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Orgenesis	78	301*	(2,098)*	9.8M	0.0 quarters	Q4 FY24 10-KDec 31, 2024
Intensity Therapeutics	9,529	not reported	(2,340)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026
Bolt Biotherapeutics	12,860	5	(6,540)*	1.9M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Zeo ScientifiX	2,265	not reported	not reported	7.8M	—	Q4 FY26 10-KTJun 30, 2026
Sunshine Biopharma	13,748	9,264	(918)*	3.9M	15.0 quarters	Q2 FY26 10-QJun 30, 2026
Neuphoria Therapeutics	19,866	year only	1,214*	5.4M	—	Q4 FY26 10-KJun 30, 2026
Processa Pharmaceuticals	196	not reported	(1,996)*	2.8M	0.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.